Vitiligo is personal, if you’re exploring treatment options for yourself or a loved one, we invite you to learn more about the Tranquillo clinical trial. Participating in the Tranquillo trial will help researchers understand if a once-daily pill is effective in treating vitiligo.

Currently, there are no approved oral medications for non-segmental vitiligo. That’s why we’re working with doctors, scientists, and the wider vitiligo community to advance a potential medicine for people across the globe.

People who chose to take part in this study will receive care from a team of dedicated healthcare professionals, and be part of a global movement progressing much-needed scientific research that will help people not just today, but for generations to come.

Who may participate

Joining a clinical trial is an important and personal decision. We thank you for taking the time to learn more and considering participation.

It’s important to remember that this is your journey and choice. You are free to stop being in this study at any time for any reason.

Everyone’s skin is different. Many factors, including genetics, race, ethnicity, and sex, can impact how people respond to a medicine. That is why it is so important that clinical trials include people of all backgrounds. The greater the diversity among clinical trial participants, the more we can learn about potential medicines, including how they work for different people. 

Condition

Nonsegmental vitiligo

Age

12+ years

Sex

Male or Female

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

View more eligibility criteria

Get started – See if you may be eligible

Answer a 2-minute questionnaire. 

A first step as you consider this clinical trial is to answer a 2-minute online questionnaire about yours or your loved one’s health and medical history. If your answers show the trial might be a good fit, you may choose to have your contact information shared with a Pfizer Clinical Trial Contact Center Navigator. 

Speak with a trial representative. 

If you’re interested, a Pfizer Clinical Trial Contact Center Navigator will call you and do a more detailed review of the trial. 

Confirm eligibility. 

Pfizer trial team members and our partners will have access to reports containing aggregated data that will not be directly linked back to you. Only the trial staff can determine if you or your loved one meets the study’s eligibility criteria and are able to enroll in the trial.

What to expect

The screening period may last up to 30 days. During this time the doctor will decide if it is right for you or your loved one to continue into the trial. The treatment period will be approximately one year long. During this time, participants will be randomly assigned to receive daily capsules (taken by mouth) of either the trial medicine or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. In this trial, more people will receive the study drug (66%, or 2 in 3) than will receive the placebo (33%, or 1 in 3).

Length of study treatment

About one year

Number of study visits

Approximately 11

An important contribution

Whether you choose to take part for yourself or your child, you and your skin have the power to advance science.

Frequently asked questions

This trial is for Nonsegmental vitiligo. What is nonsegmental vitiligo?

Nonsegmental vitiligo (also called bilateral or generalized vitiligo), is an autoimmune condition. This means the immune system attacks healthy cells; in this case, pigment (or color)-producing cells called melanocytes. The symptoms often appear on both sides of the body as symmetrical white patches.

Is this helpful?
How does the study medicine work?

The study medicine is thought to work by blocking the signals and cells in the body that are believed to cause vitiligo.

Is this helpful?
Will I receive the study medicine?

Your study group will be chosen randomly (like flipping a coin) rather than by choice. This is called randomization, and it’s one way to help avoid bias in a research study. You have a 66% chance (2 in 3) of receiving the study drug and a 33% (1 in 3) chance of receiving the placebo. Since this study is double-blinded, neither you, your study doctor, nor the study team will know if you receive the study medicine or the placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.

Is this helpful?
How is the study medicine taken?

The study medicine is a once-daily capsule that you’ll take by mouth for approximately one year. If possible, take it around the same time every day, with or without food. On study visit days, we ask that you take your dose at the site instead of at home.

Is this helpful?
Learn more
View locations for this study

    Continue exploring

    How clinical trials work

    Protecting your safety & privacy

    Steps to join a clinical trial

    FAQs